(Q36654607)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17107900%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

review article

1 reference

title

Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17107900%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17107900%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

author name string

Tony Reiman

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17107900%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Andrew R Belch

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17107900%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Linda M Pilarski

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17107900%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

publication date

1 November 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17107900%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17107900%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

volume

47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17107900%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

page(s)

2289-2300

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17107900%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17107900%20AND%20SRC:MED&resulttype=core&format=json

Non-random chromosomal rearrangements and their implications in clinical features and outcome of multiple myeloma and plasma cell leukemia

21 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

Clinical and biologic implications of recurrent genomic aberrations in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

Genomic characterization of the chromosomal breakpoints of t(4;14) of multiple myeloma suggests more than one possible aetiological mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

WHSC1, a 90 kb SET domain-containing gene, expressed in early development and homologous to a Drosophila dysmorphy gene maps in the Wolf-Hirschhorn syndrome critical region and is fused to IgH in t(4;14) multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

The third member of the transforming acidic coiled coil-containing gene family, TACC3, maps in 4p16, close to translocation breakpoints in multiple myeloma, and is upregulated in various cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

The recurrent translocation t(14;20)(q32;q12) in multiple myeloma results in aberrant expression of MAFB: a molecular and genetic analysis of the chromosomal breakpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

Correlation of TACC3, FGFR3, MMSET and p21 expression with the t(4;14)(p16.3;q32) in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

Identification of genes modulated in multiple myeloma using genetically identical twin samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

Sensitive detection using microfluidics technology of single cell PCR products from high and low abundance IgH VDJ templates in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

Genomic aberrations in plasma cell leukemia shown by interphase fluorescence in situ hybridization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

A molecular study of the t(4;14) in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

Enhanced signaling and morphological transformation by a membrane-localized derivative of the fibroblast growth factor receptor 3 kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

A novel mutation involving the carboxy terminal region of the FGFR3 gene in a multiple myeloma patient with t(4;14).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

Ribozyme cleavage leads to decreased expression of fibroblast growth factor receptor 3 in human multiple myeloma cells, which is associated with apoptosis and downregulation of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: indications for different disease entities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

Transcription repression activity is associated with the type I isoform of the MMSET gene involved in t(4;14) in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

Histone methylation in transcriptional control

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

NSD1 is essential for early post-implantation development and has a catalytically active SET domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

Set2 is a nucleosomal histone H3-selective methyltransferase that mediates transcriptional repression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

A unique mRNA initiated within a middle intron of WHSC1/MMSET encodes a DNA binding protein that suppresses human IL-5 transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

Identification of ID-1 as a potential target gene of MMSET in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

Identification of a novel IGH-MMSET fusion transcript in a human myeloma cell line with the t(4;14)(p16.3;q32) chromosomal translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190600822128

10.1080/10428190600822128

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17107900%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1 reference